Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Morphic Holding, Inc. - Common Stock (NQ:MORF)

56.99 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Morphic Holding, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
From Morphic Therapeutic
Via GlobeNewswire
MORF INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review
But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus. 
Via Investor's Business Daily
Where Morphic Holding Stands With Analysts
Via Benzinga
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 7/17
Via Investor Brand Network
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 6/5
Via Investor Brand Network
Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence
From Morphic Therapeutic
Via GlobeNewswire
Gold Moves Lower; TransCode Therapeutics Shares Surge
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher by around 30 points on Monday. The Dow traded down 0.07% to 33,939.93 while the NASDAQ rose 0.24% to... 
Via Benzinga
Topics Stocks
Exposures US Equities
Morphic Therapeutic's Stock Plunges On Monday - Here's Why?
Since Friday, Morphic Therapeutic (NASDAQ: MORF) shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 5/10
Via Investor Brand Network
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138. 
Via Benzinga
The Surprise That Prompted Morphic Therapeutic To Dump 52% Over Two Days
The company is working on a treatment for ulcerative colitis. But competitive questions linger. 
Via Investor's Business Daily
Nasdaq Turns Higher; SCYNEXIS Shares Plunge
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite trading higher on Monday. The Dow traded down 0.01% to 33,962.53 while the NASDAQ rose 0.26% to 13,246.15. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
Via Benzinga
Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023
From Morphic Therapeutic
Via GlobeNewswire
Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference
From Morphic Therapeutic
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
Via Benzinga
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
From Morphic Therapeutic
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
Via Benzinga
3 Stocks That Could Skyrocket by This Time Next Summer
The best stocks to skyrocket in June have all done well in 2023 and over the past year. They definitely ought to be on your watchlist. 
Via InvestorPlace
Morphic to Present at the Jefferies Global Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis
-Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition- 
From Morphic Therapeutic
Via GlobeNewswire
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Morphic Therapeutic
Via GlobeNewswire
More Than $47M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed lower on Thursday, there were a few notable insider trades. 
Via Benzinga
Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering
From Morphic Therapeutic
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS